Mellozzan[® ](melatonin) has gained marketing approval in Switzerland

EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Switzerland is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to Switzerland the licensee also has ongoing work for registrations and subsequent launches in Finland and the UK. In 2023, Medice launched Mellozzan[®] in Denmark and Norway and this year it was launched in Germany and Austria.

Mellozzan® is the first fast-acting melatonin product registered in Switzerland. Since before, slow-acting melatonin has been available for people over 55 with sleep difficulties, but nothing for Mellozzan's normal patient group – children with ADHD and insomnia where sleep hygiene measures have not been sufficient.

In addition to the countries covered by Medice, other partners for Mellozzan® are in various stages of registration in France, Italy, the Netherlands, Turkey and Kazakhstan. Furthermore, EQL has entered into a global license agreement covering about a hundred countries with Adalvo for Mellozzan®.
 

About Mellozzan®

Mellozzan® contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
 

About EQL

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with own GxP capabilities in development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of “Medice – The Health Family” aiming to improve patient management by offering high quality innovative drugs, non-pharmacological interventions and value adding services. For more information, please visit www.medice.com.